Canada markets close in 3 hours 21 minutes

PFE Jun 2023 52.500 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
1.5500+0.1200 (+8.39%)
As of 10:32AM EDT. Market open.
Full screen
Previous Close1.4300
Open1.1100
Bid1.3900
Ask1.4900
Strike52.50
Expire Date2023-06-16
Day's Range1.1100 - 1.5500
Contract RangeN/A
Volume23
Open Interest1.81k
  • Baystreet

    An Ideal ETF for Buy-and-Hold Investors

    If you're looking for an investment that you can buy and hold for years, you'll probably want both some ...

  • Reuters

    UPDATE 1-Pfizer/BioNTech seek FDA nod for new COVID boosters for children

    Pfizer Inc and its German partner BioNTech on Monday sought the U.S. Food and Drug Administration's authorization for an Omicron-tailored COVID-19 vaccine booster for children aged 5 through 11 years. The application comes just days after Moderna also applied for FDA authorization of its own Omicron-targeting shot in adolescents aged 12 to 17 years and children aged six to 11. The applications represent a step towards getting children vaccinated by a so-called bivalent vaccine, which targets both the original strain of the virus and the circulating BA.4 and BA.5 subvariants of Omicron.

  • Business Wire

    Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

    NEW YORK & MAINZ, Germany, September 26, 2022--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) of a 10-µg booster dose of the companies’ Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine for children ages 5 through 11 years of age. The request for Emergency Use Authorization of the Omicron BA.4/BA.5-adapted bivalent vaccine in this age group is sup